Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

@article{Ward2011AlendronateFT,
  title={Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.},
  author={Leanne Marie Ward and Frank Rauch and Michael P Whyte and Jacques D'Astous and Phillip E. Gates and Donna Roy Grogan and Edward L Lester and Richard E McCall and Thomas A Pressly and James O Sanders and P. Alex Smith and R D Steiner and Elroy Sullivan and Gayle H Tyerman and Deborah L Smith-Wright and Nadia Verbruggen and Norman Heyden and Angela Lombardi and Francis H Glorieux},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2011},
  volume={96 2},
  pages={355-64}
}
CONTEXT Information on the use of oral bisphosphonate agents to treat pediatric osteogenesis imperfecta (OI) is limited. OBJECTIVE The objective of the investigation was to study the efficacy and safety of daily oral alendronate (ALN) in children with OI. DESIGN AND PARTICIPANTS We conducted a multicenter, double-blind, randomized, placebo-controlled study. One hundred thirty-nine children (aged 4-19 yr) with type I, III, or IV OI were randomized to either placebo (n = 30) or ALN (n = 109… CONTINUE READING
54 Extracted Citations
38 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 54 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 38 references

A 2010 A randomized, controlled dose-ranging study of risedronate in chil

  • N Bishop, R Harrison, +9 authors Rigby
  • J Clin Endocrinol Metab,
  • 2011

Similar Papers

Loading similar papers…